BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
20.5.2026 12:00:00 CEST | Business Wire | Press Release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything, a campaign that uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care. The campaign launches with goalkeeping legends, including former U.S. Men’s National Team goalkeeper Tim Howard. The initiative is backed by a $300,000 community commitment for the installation of soccer mini-pitches near cancer treatment centers with the U.S. Soccer Foundation, and BeOne colleague‑driven charitable support across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520118614/en/
BeOne Medicines' One Save Changes Everything campaign uses soccer as a lens to recognize the scientific, clinical, and human moments that matter in cancer care.
John V. Oyler, Co-Founder, Chairman, and CEO, BeOne Medicines, said:
“Just like soccer is defined by save after save, progress in cancer is built moment by moment – in the lab, in the clinic, and in the communities where patients and families face it every day. ‘One Save Changes Everything’ was created to recognize the researchers who pursue targets others may have overlooked, the clinicians who act under pressure, the caregivers who show up without recognition, and the patients whose resilience fuels it all. BeOne was built for those moments: to be ready, to move with urgency, and to make sure progress reaches patients wherever they are. That belief drives everything we do.”
A Personal Connection to Cancer
A global soccer legend, Howard’s 16 saves against Belgium in 2014 – the most in international soccer history – are more than a record. They are the literal expression of the One Save Changes Everything campaign’s central belief: that preparation, presence, and the refusal to yield, applied moment after moment, can change the outcome of the most consequential events.
Howard’s connection to the campaign runs deeper than the sport. When he was 11, his grandfather was diagnosed with cancer. The ordinary evenings that followed – shared dinners, quiet walks, simply being present – he now recognizes as some of these moments.
Former U.S. Men’s National Team goalkeeper Tim Howard said:
“The moments that matter most aren’t always the ones people see. When my grandfather was sick, what stuck with me was our family showing up for him – quietly, consistently, and when it counted. Watching them taught me that being present, prepared, and willing to act can change everything. Partnering with BeOne feels natural because that’s how they show up for patients: every day, around the world, when it counts.”
Additional international goalkeepers will be announced to support the campaign alongside Tim Howard, along with voices from the cancer community that reflect BeOne’s global footprint.
Turning Purpose into Action
True to BeOne’s belief that purpose must translate into action, One Save Changes Everything extends beyond storytelling through a partnership with the U.S. Soccer Foundation. BeOne will fund the installation of soccer mini-pitches, creating spaces for movement, connection, and moments of normalcy for families affected by cancer.
Ed Foster-Simeon, President & CEO, U.S. Soccer Foundation said:
“Soccer has a unique ability to bring joy and connection in the most difficult moments. Placing mini-pitches near cancer centers creates permanent, accessible spaces for the families who need them most. We’re proud to partner with BeOne to create meaningful places for families to play.”
BeOne Colleagues Join One Save Changes Everything
BeOne’s more than 12,000 colleagues spanning six continents are the engine behind the donation commitment. For every hour an employee volunteers to support their community during the campaign period, BeOne will convert those hours into charitable dollars toward the $300,000 total to support the U.S. Soccer Foundation and other nonprofit organizations across the world.
One Save Changes Everything launches around the world today. Learn more at BeOneSave.com.
About BeOne Medicines
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook, and Instagram.
About Tim Howard
Tim Howard is one of the most accomplished goalkeepers in U.S. soccer history. He represented the U.S. Men’s National Team from 2002 to 2017 and set the FIFA World Cup record for most saves in a single match with 16 saves against Belgium in 2014 – a record that still stands. Howard played professionally for Manchester United, Everton, and the Colorado Rapids, among other clubs, over a career spanning more than two decades. He is currently a broadcaster and analyst and serves as the U.S. campaign partner for One Save Changes Everything.
To access BeOne media resources, please visit ourNewsroom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520118614/en/
Contacts
Investor Contact
Liza Heapes
+1 857-302-5663
ir@beonemed.com
Media Contact
Kyle Blankenship
+ 1 667-351-5176
media@beonemed.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom